Growth Metrics

Vertex Pharmaceuticals (VRTX) Operating Leases (2018 - 2025)

Historic Operating Leases for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Q3 2025 value amounting to $1.8 billion.

  • Vertex Pharmaceuticals' Operating Leases rose 1086.4% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 1086.4%. This contributed to the annual value of $1.5 billion for FY2024, which is 30461.1% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Operating Leases of $1.8 billion as of Q3 2025, which was up 1086.4% from $1.5 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Operating Leases high stood at $1.8 billion for Q3 2025, and its period low was $354.4 million during Q3 2023.
  • Its 5-year average for Operating Leases is $714.8 million, with a median of $381.7 million in 2023.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Operating Leases tumbled by 1083.86% in 2023 and then skyrocketed by 36698.65% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Operating Leases (Quarter) stood at $410.7 million in 2021, then grew by 4.24% to $428.1 million in 2022, then decreased by 10.84% to $381.7 million in 2023, then soared by 304.61% to $1.5 billion in 2024, then grew by 18.8% to $1.8 billion in 2025.
  • Its Operating Leases was $1.8 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.5 billion in Q1 2025.